STOCK TITAN

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Solid Biosciences Inc. (Nasdaq: SLDB) has announced participation in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 a.m. ET. Ilan Ganot, CEO, and Carl Morris, Chief Scientific Officer, will represent the company. A live webcast will be available on the investor relations website, with a replay accessible after the event. Solid Biosciences is dedicated to developing transformative treatments for Duchenne muscular dystrophy, focusing on gene therapy candidates SGT-001 and SGT-003.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, Co-Founder and President, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET.

A live webcast will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com


FAQ

What is the date and time of Solid Biosciences' presentation at the Jefferies Healthcare Conference?

Solid Biosciences will present on June 10, 2022, at 10:30 a.m. ET.

Who will represent Solid Biosciences at the Jefferies Healthcare Conference?

Ilan Ganot, CEO, and Carl Morris, Chief Scientific Officer, will represent Solid Biosciences.

Where can I watch the Solid Biosciences fireside chat live?

The live webcast can be accessed on Solid Biosciences' investor relations website.

What are the names of Solid Biosciences' gene therapy candidates?

The gene therapy candidates are SGT-001 and SGT-003.

What disease is Solid Biosciences focused on treating?

Solid Biosciences is focused on treating Duchenne muscular dystrophy.

Solid Biosciences Inc.

NASDAQ:SLDB

SLDB Rankings

SLDB Latest News

SLDB Stock Data

160.22M
32.71M
0.91%
90.08%
3.81%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CHARLESTOWN